NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules ...Middle East

$20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants are expected to provide cash runway to complete the Phase 1 Part 3 clinical trial CAMBRIDGE, Mass., June 24, 2024 /PRNewswire/ --...

Hence then, the article about neurobo pharmaceuticals announces up to 70 million concurrent private placement and registered direct offering priced at the market under nasdaq rules was published today ( Monday 24/06/2024 - 03:04 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules )

Also on site :

• Iranian Foreign Minister spokesperson in exclusive interview discusses cause of the war and Iran’s stance
• Walmart’s 'Very Sturdy' $53 3-Piece Patio Set Is Perfect for Small-Space Entertaining
• ‘Inflationary surge’: Fed economists warn AI hype is overheating the economy whether or not the technology ever delivers